Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells

Fig. 1

Schematic representation of type I and type II combi-molecules. Upon entering the cells, type I combi-molecules are able to bind and inhibit their target as intact molecules. In the cells, the molecule is hydrolyzed to release an inhibitor ‘A’ and a DNA damaging agent ‘B’. Type II combi-molecules enter the cells and are able to inhibit their target and damage DNA without hydrolysis. Inhibition of the target can synergize with the effects of the DNA damaging species

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us